Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5397_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
15
Добавлен:
15.09.2026
Размер:
15 Мб
Скачать
☆
15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
scaffold facilitated the gradual release of silver, yet it did not decrease toxicity to host cells (Mohiti-Asli etal. 2014). Continued research in this domain might be very benecial.
309
15.3 Eliminating Anti-infective Drug Resistance
The development of resistance to pathogens is a major and increasing challenge in the ght against IDs. Pathogens may acquire resistance by a number of mecha­nisms, including the production of drug-inactivating enzymes, an intracellular life cycle, biolm formation, decreased metabolic activity, or the fact that they are obli­gate intracellular pathogens (Munita and Arias 2016). Ineffectiveness against intra­cellular infections may be caused by poor drug diffusion through the membrane of the host cells and its active efux via drug transporters (Carryn etal. 2003). Since pathogens and drug molecules are not colocalized inside host cells, effectiveness is reduced, adding another layer of complication. Aminoglycosides, for instance, pre­fer to accumulate in the lysosomes, making them useless against cytosolic patho­gens (Tulkens and Trouet 1978). Therefore, methods that boost drug accumulation within cells and direct medications to specic subcellular sites may be more effec­tive. By enclosing anti-infectives in NCs, it may be possible to improve their absorp­tion by cells and to modify their intracellular disposition. Improvements in gentamicin administration to cytoplasmic organisms like Listeria monocytogenes and Salmonella typhimurium were tried by Lutwyche etal. (1998). Fusogenic lipo­somes, which are stable at neutral pH but dissolve in the acidic environment of endolysosomes, were used to encapsulate gentamycin. The medication is released into the cytoplasm as the endosomal membrane is destabilized by lipid fusion. The scientists used two liposomal formulations, one having a uorescence resonance energy transfer pair and the other without, to verify the acid-mediated disintegration of the liposomes. This mixture’s low baseline uorescence was due to the closeness of the uorescent molecules. However, when the solution was made acidic, the lipo­somes ruptured and the lipids mingled, which dequenched the uorescence. Gentamicin loaded into pH-sensitive liposomes was three times as effective as the free antibiotic in an invitro model of infection with recombinant S. typhimurium. Although pH-insensitive liposomes were taken up by cells to a greater extent, their activity lagged behind that of the pH-sensitive formulation. The authors uores­cently labeled liposomes that were released and metabolized by cellular enzymes to investigate the process. Only pH-sensitive liposomes produced the marker intracel­lularly in mouse macrophages, as shown by confocal imaging. Balomycin, an endosome acidication inhibitor, suppressed marker release. The importance of intracellular targeting was shown, and the molecular specics of the roles played by each component of the formulation were presented in this work.
Clemens et al. (2012) developed mesoporous silicon NPs with isoniazid to target intracellular M. tuberculosis. The NPs’ pores were sealed with β-cyclodextrin, effectively preventing drug leakage under neutral pH conditions. However, as the
310
https://t.me/med1917
S. Banerjee et al.
pH becomes acidic, the plug dissolves, leading to the release of the medication. Sémiramoth etal. (2012) chemically linked penicillin G to hydrophobic squalene by a pH-sensitive ester bond. The cells quickly internalized NPs produced from this combination and then released the drug inside the endolysosomes. Consequently, there was enhanced efcacy compared to the unbound medication. The process of analyzing and understanding the ways by which bacteria take up NCs on their surface has been utilized to enhance the transport of substances within cells. Invasin, a protein produced by Yersinia pseudotuberculosis, attaches to integrins on the surface of host cells. This attachment leads to a rearrangement of the host cell’s cytoskeleton and allows the bacteria to be taken up into mem­brane-bound structures. Labouta etal. (2015) conducted reverse engineering of this process by linking liposomes to the C-terminal portion of invasin, known as InvA497, on the surface. Confocal microscopy investigations conducted in Hep-2 cells demonstrated that InvA497-functionalized liposomes exhibited a signicant increase in cell binding (>30-fold) compared to albumin-functionalized lipo­somes. Furthermore, this enhanced cell binding was eliminated in competition trials. InvA497-functionalized gentamycin-loaded liposomes exhibited a 30% decrease in bacterial load in a laboratory model of Y. pseudotuberculosis infec- tion, but albumin-functionalized liposomes did not have any impact. This study has shown that the addition of InvA497 to the surface of polymeric NPs has posi­tive effects on both the absorption of the NPs by cells in a laboratory context and their ability to kill microbes. This notion is incredibly creative and would benet from in vivo examination. Moreover, if these systems are administered orally, then it is crucial to comprehend the stability of the peptides in the enzyme-abun­dant gastrointestinal environment. Understanding the immune response to sys­temically delivered NCs functionalized with bacterial peptides is crucial for determining their pharmacokinetics and tolerability.
Efcient intracellular transport is crucial for molecules like messenger RNA, which have garnered signicant interest for their use in immunization. The majority of nucleic acid and protein delivery systems that are based on polymers are inuenced by the pioneering research conducted by Langer and Folkman (1976). Their work demonstrated that macromolecules, including proteins, could be enclosed within small carriers made of polymers. This was initially considered improbable because of the usage of organic solvents in the synthe­sizing process and the perceived impermeability of polymers to macromolecules (Ditlev et al. 2018). After successfully demonstrating the proof-of-concept using polymers, researchers showed how RNA could be encapsulated in lipid carriers and its usefulness in immunization. NCs play a crucial role in facilitat­ing the transportation of mRNA through the cellular membranes, allowing for endolysosomal escaping and the release of nucleic acid in the cytoplasm. For instance, self-replicating mRNA that codes for an antigen protein was combined with a polymer based on cationic dendrimers. Animals that received mRNA NPs exhibited immunological responses characterized by the production of antibod­ies and the activation of CD8+ T-cells. Furthermore, these animals were fully shielded against fatal infections caused by Toxoplasma gondii, H1N1 inuenza,
15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
and Ebola virus. Clinical trials have examined mRNA vaccines using lipid NCs, with participation from industries like Moderna, BioNTech, Acuitas Therapeutics, Pzer, GlaxoSmithKline, Translate Bio, Sano, and others. Preliminary ndings demonstrate that lipid-NP-formulated mRNA vaccines tar­geting SARS-CoV-2 and H7N9, H10N8 inuenza viruses are well tolerated and elicit a strong humoral response (Jackson et al. 2020; Feldman et al. 2019). More precisely, mRNA-based vaccines have shown a level of effectiveness over 90% in combating SARS-CoV-2. The long-term viability of mRNA-based vac­cinations over extended storage and transportation may pose signicant chal­lenges to their usage in resource-constrained environments. NPs containing peptide-based antigens have been produced for the purpose of vaccinating against SARS-CoV-2 (Tian etal. 2021). Nanoencapsulation has been utilized to target antibiotics to intracellular vesicles since bacteria and NCs have the ability to aggregate in these vesicles. Couvreur etal. demonstrated the co-localization of poly(cyanoacrylate) NPs with S. typhimurium in phagosomes of macrophages utilizing confocal and transmission electron microscopy. This led to an improved targeting of ampicillin inside the cells (Pinto-Alphandary etal. 1994). Toti etal. ( 2011) conducted a separate investigation and discovered that PLGA NPs, which contained a uorescent dye, gathered together with chlamydial inclusion bodies in infected human lung epithelial cells (Toti etal. 2011). Experiments conducted in a controlled laboratory environment showed that antibiotics (rifampicin and azithromycin) were shown to be efcacious when administered promptly after infection, but their effectiveness diminished when administered after 24 or 48h. Nevertheless, the activities of the NPs were partially recovered even when administered 24 and 48h after infection. NPs possess the ability to hinder, interrupt, or disseminate bacteria found in biolm infections (Han etal.
2017). The extracellular polymeric matrix in the biolm acts as a diffusion bar-
rier, providing protection to bacteria against elevated antibiotic concentrations, which often results in the development of persistent infections. Teirlinck etal. (2018) demonstrated that when gold NPs were exposed to laser irradiation, nanobubbles were developed, which caused the diffusion barrier to be disrupted. The local disturbance of the biolms resulted in heightened permeability, thereby rendering them more susceptible to the antibiotic tobramycin.
311
15.4 Clinical andPreclinical Nanotechnology Advancements
This section focuses on the modern nanotechnologies used in the treatment of important infectious diseases such as tuberculosis, malaria, and HIV infection. The information indicates that nanotechnology has been extensively researched in clini­cal contexts and with large animals for the purpose of treating and preventing HIV infection. Conversely, nanotechnology was explored with less enthusiasm for TB and malaria. These IDs have mostly been tested in preclinical experiments involving animals. The data are listed in Table15.1.
312
https://t.me/med1917
S. Banerjee et al.
Reduced dose frequency
Reactions at injection
sites are rather frequent,
refrigeration required
(NCT04542070,
NCT02938520,
Cabotegravir
Reduced dose
frequency
Daily dosing is required Omits potentially harmful excipients
caregiver
NCT02951052)
(rodent model)
Optimal drug transport to the lungs
Improved bio-availability, target alveolar
Macrophages, avoid rst-pass metabolism
Reduced dose frequency, improved
bio-availability
Superior bio-availability compared to oral
forms, reduced dose frequency
Improved bio-availability
training
BCG vaccine Will need patient
Frequent dosing is
required, devoid of
pyrazinamide–ethambutol–
streptomycin
pyrazinamide
ethambutol
caregiver
Target contaminated erythrocytes, enhance
the lipophilic drug’s solubility
microemulsions with the
use of high surfactant
concentrations
Needs the help of a
caregiver
Chloroquine derivative (novel
aminoalcohol derivative)
Disease
name Formulation Drug name Testing phase Limitation Advancement
Table 15.1 Nanotechnology for the treatment of IDs in preclinical and clinical facilities (https://clinicaltrials.gov/)
HIV Injectable NPs Rilpivirine Phase III
Oral NPs Lopinavir–efavirenz Preclinical
Injectable NPs Dolutegravir Needs the help of a
Injectable lipid NPs Lopinavir–ritonavir–tenofovir Target macrophages
TB Aerosolized
micro-NPs
Oral polymer NPs Rifampicin–isoniazid–
Oral lipid NPs Rifampicin–isoniazid–
Microemulsion Artemether–tafenoquine Stabilizing
Malaria Injectable NPs Artemether–lumefantrine Needs the help of a
Injectable
immune- liposomes
15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
313
15.5 Limitations andFuture Prospects
The aforementioned examples demonstrate several potential therapeutic approaches in the development of nanomedicines for the treatment and prevention of infectious diseases. Nevertheless, in order to have the greatest inuence, nano­technology approaches must surmount several economic, commercial, and regu­latory obstacles. Initially, the primary challenge is in minimizing the expenses associated with the development of novel medications and nanotechnology-driven systems. The discovery of novel pharmaceuticals for global health solutions is a costly endeavor.
Repurposing established medications inside NCs might potentially attain com­parable objectives of heightened effectiveness and safety at a much-reduced cost. Nevertheless, a single nano-system that has been ofcially sanctioned (namely, an amphotericin B liposomal formulation) is not economically viable in poor nations (Sundar and Chakravarty 2010). The inclusion of excipients, such as lyoprotectants, in nanosystems may lead to an increase in the overall cost of various therapies. Furthermore, the production and preservation circumstances of some NPs might not be suitable for low-resource countries (Mitchell and Carlson 2018). Researchers must ensure the repeatability and scalability of these nanosystems while also taking into account their environmental impact.
Nanomedicines are expected to be complex structures consisting of numer­ous components arranged in certain spatial congurations. Minor alterations in procedure or structure may have a negative impact on the exact construction of nanomedicines (Desai 2012; Ioannidis etal. 2018). Furthermore, the presence of regional and national variations within and across regulatory bodies poses a signicant problem, particularly when conducting multinational clinical trials. Ultimately, it is crucial to consider the level of acceptance among patients about these nanosystems. Legal action was taken against the FDA in 2006 by the International Centre for Technology Assessment and other consumer groups who claimed the agency was too slow to regulate products using nanomaterials. In light of recent developments, the FDA formed the Nano Task Force. An inter­connected group of stakeholders must collaborate for the effective implementa­tion of nanomedicines into clinical practice. This includes individuals from the academic eld, investors from many industries, government representatives, and contract research and production organizations. Nanotechnology is a multidis­ciplinary area that necessitates the use of intellectual property and commercial­ization methods in order to expand and develop. However, the rapid application of nanotechnologies from the laboratory to the general population and the sig­nicant inuence these systems have made on the SARS-CoV-2 epidemic pro­vide considerable potential. This example implies that such achievements may be feasible in addressing other contagious illnesses as well.
314
https://t.me/med1917
S. Banerjee et al.
15.6 Conclusions
Identication numbers have a signicant inuence on the occurrence of illness and death worldwide, with a particularly severe effect on nations with low SDI.Enhancing the accessibility and effectiveness of medications may enhance the patients’ well­being and alleviate the impact of diseases. This chapter focuses on the use of nanotechnology- based methods to enhance oral medication delivery, reduce the fre­quency of drug administration, and target drugs to specic infection areas, hence enhancing the effectiveness of therapy. Ultimately, it examined instances of nano­technologies now undergoing clinical trials for HIV therapy and in the preclinical stage of development for TB and malaria treatment. Nanotechnologies that are both innovative and cost-effective, and specically designed to address the issues faced by low-SDI nations, are expected to have the most positive impact on patients.
References
Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR et al (2007)
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergil-
losis. J Infect 55(1):68–74 Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. Bioeng Transl Med 1(1):10–29 Arias JL, Unciti-Broceta JD, Maceira J, Del Castillo T, Hernández-Quero J, Magez S etal (2015)
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. J
Control Release 197:190–198 Azad AK, Rajaram MV, Schlesinger LS (2014) Exploitation of the macrophage mannose receptor
(CD206) in infectious disease diagnostics and therapeutics. J Cytol Mol Biol 1(1):1000003 Bakker-Woudenberg IA, Lokerse AF, ten Kate MT, Storm G (1992) Enhanced localization of lipo-
somes with prolonged blood circulation time in infected lung tissue. Biochim Biophys Acta
Mol Basis Dis 1138(4):318–326 Bakker-Woudenberg I, Lokerse AF, Mt K, Mouton J, Woodle M, Storm G (1993) Liposomes with
prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung
tissue. J Infect Dis 168(1):164–171 Carryn S, Chanteux H, Seral C, Mingeot-Leclercq M-P, Van Bambeke F, Tulkens PM (2003)
Intracellular pharmacodynamics of antibiotics. Infect Dis Clin 17(3):615–634 Clemens DL, Lee B-Y, Xue M, Thomas CR, Meng H, Ferris D etal (2012) Targeted intracel-
lular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macro-
phages via functionalized mesoporous silica nanoparticles. Antimicrob Agents Chemother
56(5):2535–2545 Cu Y, Booth CJ, Saltzman WM (2011) In vivo distribution of surface-modied PLGA nanopar-
ticles following intravaginal delivery. J Control Release 156(2):258–264 Cunha-Reis C, Machado A, Barreiros L, Araújo F, Nunes R, Seabra V etal (2016) Nanoparticles-
in- lm for the combined vaginal delivery of anti-HIV microbicide drugs. J Control Release
243:43–53 das Neves J, Nunes R, Machado A, Sarmento B (2015) Polymer-based nanocarriers for vaginal
drug delivery. Adv Drug Deliv Rev 92:53–70 Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J
14(2):282–295
15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
Ditlev JA, Case LB, Rosen MK (2018) Who’s in and who’s out—compositional control of biomo-
lecular condensates. J Mol Biol 430(23):4666–4684 Duong HT, Jung K, Kutty SK, Agustina S, Adnan NNM, Basuki JS etal (2014) Nanoparticle (star
polymer) delivery of nitric oxide effectively negates Pseudomonas aeruginosa biolm forma-
tion. Biomacromolecules 15(7):2583–2589 Ensign LM, Tang BC, Wang Y-Y, Tse TA, Hoen T, Cone R et al (2012) Mucus-penetrating
nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med
4(138):138ra79-ra 79 Feldman RA, Fuhr R, Smolenov I, Ribeiro AM, Panther L, Watson M etal (2019) mRNA vaccines
against H10N8 and H7N9 inuenza viruses of pandemic potential are immunogenic and well
tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37(25):3326–3334 Fielding RM, Lewis RO, Moon-McDermott L (1998) Altered tissue distribution and elimination
of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®). Pharm Res
15:1775–1781 Han C, Romero N, Fischer S, Dookran J, Berger A, Doiron AL (2017) Recent developments in the
use of nanoparticles for treatment of biolms. Nanotechnol Rev 6(5):383–404 Huh AJ, Kwon YJ (2011) “Nanoantibiotics”: a new paradigm for treating infectious diseases using
nanomaterials in the antibiotics resistant era. J Control Release 156(2):128–145 Hussain S, Joo J, Kang J, Kim B, Braun GB, She Z-G etal (2018) Antibiotic-loaded nanoparticles
targeted to the site of infection enhance antibacterial efcacy. Nature Bio Eng 2(2):95–103 Huth M, Ricci A, Cheng A (2011) Mechanisms of aminoglycoside ototoxicity and targets of hair
cell protection. Int J Otol 2011:937861 Ioannidis JP, Kim BY, Trounson A (2018) How to design preclinical studies in nanomedicine and
cell therapy to maximize the prospects of clinical translation. Nat Biol Eng 2(11):797–809 Irvine DJ, Hanson MC, Rakhra K, Tokatlian T (2015) Synthetic nanoparticles for vaccines and
immunotherapy. Chem Rev 115(19):11109–11146 Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN etal (2020) An
mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med 383(20):1920–1931 James GA, Swogger E, Wolcott R, Ed P, Secor P, Sestrich J etal (2008) Biolms in chronic
wounds. Wound Repair Regen 16(1):37–44 Jawahar N, Meyyanathan S (2012) Polymeric nanoparticles for drug delivery and targeting: a
comprehensive review. Int J Health Allied Sci 1(4):217 Kaminishi H, Tanaka M, Cho T, Maeda H, Hagihara Y (1990) Activation of the plasma kallikrein-
kinin system by Candida albicans proteinase. Infect Immun 58(7):2139–2143 Kim M-H, Yamayoshi I, Mathew S, Lin H, Nayfach J, Simon SI (2013) Magnetic nanoparti-
cle targeted hyperthermia of cutaneous Staphylococcus aureus infection. Ann Biomed Eng
41:598–609 Kinch MS, Patridge E, Plummer M, Hoyer D (2014) An analysis of FDA-approved drugs for infec-
tious disease: antibacterial agents. Drug Discov Today 19(9):1283–1287 Kirtane AR, Langer R, Traverso G (2016) Past, present, and future drug delivery systems for anti-
retrovirals. J Pharm Sci 105(12):3471–3482 Labouta HI, Menina S, Kochut A, Gordon S, Geyer R, Dersch P etal (2015) Bacteriomimetic
invasin-functionalized nanocarriers for intracellular delivery. J Control Release 220:414–424 Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R etal (2007) Rapid transport of large
polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci 104(5):1482–1487 Landovitz RJ, Kofron R, McCauley M (2016) The promise and pitfalls of long acting injectable
agents for HIV prevention. Curr Opin HIV AIDS 11(1):122 Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromol-
ecules. Nature 263(5580):797–800 Laverman P, Boerman OC, Oyen WJ, Dams ETM, Storm G, Corstens FH (1999) Liposomes for
scintigraphic detection of infection and inammation. Adv Drug Deliv Rev 37(1–3):225–235 Leal J, Smyth HD, Ghosh D (2017) Physicochemical properties of mucus and their impact on
transmucosal drug delivery. Int J Pharm 532(1):555–572
315
316
https://t.me/med1917
Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J (1998) Body distribution of azidothy-
midine bound to hexyl-cyanoacrylate nanoparticles after IV injection to rats. J Control Release
50(1–3):21–30 Lutwyche P, Cordeiro C, Wiseman DJ, St-Louis M, Uh M, Hope MJ etal (1998) Intracellular
delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes.
Antimicrob Agents Chemother 42(10):2511–2520 Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled
drug delivery carrier. Polymers 3(3):1377–1397 Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA (2021) Targeted drug deliv-
ery strategies for precision medicines. Nat Rev Mater 6(4):351–370 Martinez LR, Han G, Chacko M, Mihu MR, Jacobson M, Gialanella P etal (2009) Antimicrobial
and healing efcacy of sustained release nitric oxide nanoparticles against Staphylococcus
aureus skin infection. J Invest Dermatol 129(10):2463–2469 McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B etal (2018) Pharmacokinetics
of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob Agents
Chemother 62(1):10.1128/aac. 01316-17 Mitchell SL, Carlson EE (2018) Tiny things with enormous impact: nanotechnology in the ght
against infectious disease. ACS infect dis 4(10):1432–1435 Mohiti-Asli M, Pourdeyhimi B, Loboa EG (2014) Skin tissue engineering for the infected wound
site: biodegradable PLA nanobers and a novel approach for silver ion release evaluated in a
3D coculture system of keratinocytes and Staphylococcus aureus. Tissue Eng Part C Methods
20(10):790–797 Molla A, Yamamoto T, Akaike T, Miyoshi S, Maeda H (1989) Activation of Hageman fac-
tor and prekallikrein and generation of kinin by various microbial proteinases. J Biol Chem
264(18):10589–10594 Munita JM, Arias CA.Mechanisms of antibiotic resistance. Virulence mechanisms of bacterial
pathogens 2016: 4 (2) 481–511 Nafee N, Husari A, Maurer CK, Lu C, de Rossi C, Steinbach A etal (2014) Antibiotic-free nano-
therapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary
delivery and anti-virulence efcacy of novel quorum sensing inhibitors. J Control Release
192:131–140 Palliser D, Chowdhury D, Wang Q-Y, Lee SJ, Bronson RT, Knipe DM etal (2006) An siRNA-
based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature
439(7072):89–94 Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines—a new era in vaccinology.
Nat Rev Drug Discov 17(4):261–279 Pheage T (2017) Dying from lack of medicines. Afr Renew 30(3):24–25 Pinto-Alphandary H, Balland O, Laurent M, Andremont A, Puisieux F, Couvreur P (1994)
Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages
infected invitro with Salmonella typhimurium. Pharm Res 11:38–46 Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N etal (2018) Global, regional,
and national age-sex-specic mortality for 282 causes of death in 195 countries and territo-
ries, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet
392(10159):1736–1788 Roy I, Vij N (2010) Nanodelivery in airway diseases: challenges and therapeutic applications.
Nanomedicine 6(2):237–244 Sabaté E (2003) Adherence to long-term therapies: evidence for action. World Health Organization Sarathy JP, Zuccotto F, Hsinpin H, Sandberg L, Via LE, Marriner GA etal (2016) Prediction of
drug penetration in tuberculosis lesions. ACS Infect Dis 2(8):552–563 Schiffelers R, Storm G, Bakker-Woudenberg I (2001) Liposome-encapsulated aminoglycosides in
pre-clinical and clinical studies. J Antimicrob Chemother 48(3):333–344
S. Banerjee et al.
15 Biotechnological Approaches inInfectious Diseases
https://t.me/med1917
Semiramoth N, Meo CD, Zouhiri F, Said-Hassane F, Valetti S, Gorges R etal (2012) Self-assembled
squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular
infections. ACS Nano 6(5):3820–3831 Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK etal (2009) Human skin wounds:
a major and snowballing threat to public health and the economy. Wound Repair Regen
17(6):763–771 Siegel RA, Kirtane AR, Panyam J (2016) Assessing the benets of drug delivery by nanocarriers: a
partico/pharmacokinetic framework. IEEE Trans Biomed Eng 64(9):2176–2185 Steinbach JM, Weller CE, Booth CJ, Saltzman WM (2012) Polymer nanoparticles encapsulating
siRNA for treatment of HSV-2 genital infection. J Control Release 162(1):102–110 Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin J-MG etal (2011) N-acetylcysteine
enhances cystic brosis sputum penetration and airway gene transfer by highly compacted
DNA nanoparticles. Mol Ther 19(11):1981–1989 Sundar S, Chakravarty J (2010) Liposomal amphotericin B and leishmaniasis: dose and response.
J Global Infect Dis 2(2):159 Tedijanto C, Olesen SW, Grad YH, Lipsitch M (2018) Estimating the proportion of bystander
selection for antibiotic resistance among potentially pathogenic bacterial ora. Proc Natl Acad
Sci 115(51):E11988–E11E95 Teirlinck E, Xiong R, Brans T, Forier K, Fraire J, Van Acker H etal (2018) Laser-induced vapour
nanobubbles improve drug diffusion and efciency in bacterial biolms. Nat Commun
9(1):4518 Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H etal (2021) SARS-CoV-2 spike
glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in
mice. Nat Commun 12(1):372 Toti US, Guru BR, Hali M, McPharlin CM, Wykes SM, Panyam J etal (2011) Targeted delivery
of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials
32(27):6606–6613 Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S (2015) Formulation and pharmacology of long-
acting cabotegravir. Curr Opin HIV AIDS 10(4):239 Tulkens P, Trouet A (1978) The uptake and intracellular accumulation of aminoglycoside antibiot-
ics in lysosomes of cultured rat broblasts. Biochem Pharmacol 27(4):415–424 Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL etal (2006) Single dose
and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 63(2):95–102 Williams PE, Crauwels HM, Basstanie ED (2015) Formulation and pharmacology of long-acting
rilpivirine. Curr Opin HIV AIDS 10(4):233–238 Wistrand-Yuen E, Knopp M, Hjort K, Koskiniemi S, Berg OG, Andersson DI (2018) Evolution of
high-level resistance during low-level antibiotic exposure. Nat Commun 9(1):1599 Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schoeld LN (2003) Liposome delivery
of ciprooxacin against intracellular Francisella tularensis infection. J Control Release
92(3):265–273 World Health Organization, and Stop TB Initiative. (2010) Treatment of tuberculosis: guidelines.
World Health Organization, Geneva Xiong MH, Li YJ, Bao Y, Yang XZ, Hu B, Wang J (2012a) Bacteria-responsive multifunctional
nanogel for targeted antibiotic delivery. Adv Mater 24(46):6175–6180 Xiong M-H, Bao Y, Yang X-Z, Wang Y-C, Sun B, Wang J (2012b) Lipase-sensitive polymeric
triple-layered nanogel for “on-demand” drug delivery. J Am Chem Soc 134(9):4355–4362 Zhang CY, Gao J, Wang Z (2018) Bioresponsive nanoparticles targeted to infectious microenviron-
ments for sepsis management. Adv Mater 30(43):1803618
317
Chapter 16
https://t.me/med1917
Forensic Drug Chemistry: Unravelling Evidence Through Scientic Analysis
AbuMdAshifIkbal, RabinDebnath, SabuThomas, DebprasadChattopadhyay, andParthaPalit
Abstract Forensic drug chemistry plays a pivotal role in modern criminal investi-
gations by utilising scientic methods to identify, analyse, and interpret illicit sub­stances at crime scenes. This interdisciplinary eld merges principles from chemistry, pharmacology, and law enforcement to provide accurate and reliable evidence that assists in establishing connections between individuals, substances, and criminal activities. The primary objective of forensic drug chemistry is to deter­mine the presence and composition of controlled substances, such as illegal drugs and prescription medications, in various samples recovered from crime scenes. The constant emergence of new designer drugs, synthetic compounds, and modied substances necessitates continuous research and method development to ensure accurate identication and classication. The results obtained from forensic analy­ses can determine the course of an investigation, inuence legal decisions, and impact the lives of both victims and suspects. Moreover, forensic drug chemistry extends beyond identifying substances; it aids in uncovering patterns of drug traf­cking, manufacturing, and distribution. In conclusion, forensic drug chemistry stands as an indispensable component of modern forensic science. Through its sci­entic rigour and multidisciplinary approach, this area provides crucial information
A. M. A. Ikbal · P. Palit (*) Department of Pharmaceutical Sciences, Drug Discovery Research Laboratory, Assam University (A Central University), Silchar, India
R. Debnath ISF College of Pharmacy, Moga, Punjab, India
S. Thomas School of Chemical Sciences, Mahatma Gandhi University, Kottayam, India e-mail: sabu.thomas@mgu.ac.in
D. Chattopadhyay Natural product, ICMR-National Institute of Traditional Medicine, Nehru Nagar, Belagavi, Karnataka, India
ICMR-National Institute of Traditional Medicine, Belagavi, India
School of Life Sciences, Swami Vivekananda University Barrackpore, Kolkata, India
Ltd. 2024 S. Bose et al. (eds.), Concepts in Pharmaceutical Biotechnology and Drug Development, Interdisciplinary Biotechnological Advances,
https://doi.org/10.1007/978-981-97-1148-2_16
319© The Author(s), under exclusive license to Springer Nature Singapore Pte